Please enter a keyword
EN
CN
JP
About Sungen
Company Profile
Milestones
Social Responsibilities
Contact Us
Join Us
Research & Development
Research Platforms
Research Centers
Research Institutes
New Raw Materials of Pharmaceutical
Innovative Manufacture
Lighthouse Factory
Biofabrication
Key Control System
Quality Management
Authoritative Certification
Clinical Research
Real-World Study
Research Fund
Research Papers Published
Brand ANI
Products
Production of Anticancer Drug Paclitaxel by
Fungal Fermentation
Project Introduction
R&D Process
Patent Certification
    Paclitaxel is one of the most effective anticancer drugs in the world. It is used to treat ovarian cancer, breast cancer, non-small cell lung cancer, esophageal cancer and many other cancers. Paclitaxel raw materials on the market are mainly extracted from the bark of Taxus chinensis, a rare plant protected by the state. Due to the dual constraints of resource shortage and ecological protection, there is a huge market gap and the price of paclitaxel is expensive.

    Sungen produces paclitaxel through fungal fermentation, which does not need to be restricted by the shortage of yew trees, and completely solves the "bottleneck" problem restricting paclitaxel production. Secondly, protect the precious yew tree resources, avoid environmental pollution and realize the ecological benefits of green environmental protection. Fungal fermentation has the advantages of short production cycle, low investment and stable product quality, which can meet the market demand to a greater extent.

Year 1991            

Dr. Jiepeng Chen and his core R&D team started the research on paclitaxel. 


Year 1995-1996    

Dr. Chen`s team went to the yew producing area for sampling.


Year 1997-2000    

Completed the identification of paclitaxel strains；

The project “Application of genetically engineered strain Phargen AA-026 for fermentation and production of anticancer drug paclitaxel” received the first batch of funding support from the Innovation Fund from the Ministry of Science and Technology of China.


Year 2001-2005   

Completion of a small-scale pilot study on paclitaxel；

The project “Application of genetically engineered strain Phargen AA-026 for fermentation and production of anticancer drug paclitaxel” completed  and acceptance by the Ministry of Science and Technology of China；

Proprietary brand FUNGXOL® is established, base on the project R&D development results.

Year 2006-2010    

Completed the mid-scale pilot study of paclitaxel；

The project“Production of paclitaxel by fermentation of genetically engineered bacterium "ST026”recived funding from “Key breakthrough projects in key areas in Guangdong and Hong Kong in 2006”.

Year 2011-2015    

The project“Production of paclitaxel by fermentation of genetically engineered bacterium “granted four invention patents at home and abroad.


  • Technology Patent （Patent No. ：ZL 03 1 09244.6）
  • Chinese National Invention Patent （ Patent No. ：ZL 200410169347.8）
  • International Invention Patent （ Patent No. ：WO 2006/009518 A1）
  • U.S. Patent for Invention （ Patent No. ：US 2007/0218531 A1）
  • European invention patents ：EP1781773

About Us
Research & Development
Innovative Manufacture
Clinical Research
Brand ANI
Products
Join Us
COPYRIGHT © 2019 Guangdong Sungen Bioscience Co., Ltd.
Guangdong ICP 15051377-4
Powered by Fractal-technology
The basic information